![]()  | |
| Clinical data | |
|---|---|
| ATC code | 
  | 
| Legal status | |
| Legal status | 
  | 
| Identifiers | |
  | |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| Chemical and physical data | |
| Formula | C18H22N4O2 | 
| Molar mass | 326.400 g·mol−1 | 
| 3D model (JSmol) | |
  | |
  | |
EGIS-7625 is a selective and competitive 5-HT2B receptor antagonist. It is experimentally proven to be directly associated with smooth stomach muscle constriction of white rats in vivo, and variably effective in provoking a similar response in in vitro human stomach cells. In high blood concentrations, it causes mild constriction of rabbit pulmonary arteries.[1]
References
| Simple piperazines (no additional rings)  | |
|---|---|
| Phenylpiperazines | 
  | 
| Benzylpiperazines | |
| Diphenylalkylpiperazines (benzhydrylalkylpiperazines)  | 
  | 
| Pyrimidinylpiperazines | |
| Pyridinylpiperazines | |
| Benzo(iso)thiazolylpiperazines | |
| Tricyclics (piperazine attached via side chain)  | 
  | 
| Others/Uncategorized | |
    This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.
